{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:17:05Z","timestamp":1791818225443,"version":"4.3.4"},"reference-count":36,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Flt3L is a biomarker of progenitor cell mass in AML. Measurement of Flt3L during induction chemotherapy and follow-up provides prognostic information.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000197","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T19:08:00Z","timestamp":1571771280000},"page":"3052-3061","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8278-0463","authenticated-orcid":false,"given":"Paul","family":"Milne","sequence":"first","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wilhelm-Benartzi","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3017-2474","authenticated-orcid":false,"given":"Venetia","family":"Bigley","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, Strand, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham Edgbaston, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Immune Monitoring Laboratory, Massachusetts General Hospital Center for Cancer Research, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Publicover","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pagan","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Grech","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Haematology, Nottingham University Hospital, Nottingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark","family":"Levis","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-9586","authenticated-orcid":false,"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom"},{"name":"NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"2019111600301372500_B1","unstructured":"CRUK\n          . Cancer statistics for the UK. Available at: www.cancerresearchuk.org\/health-professional\/cancer-statistics. Accessed 1 December 2018."},{"key":"2019111600301372500_B2","unstructured":"SEER\n          . statfacts. Available at: https:\/\/seercancergov\/statfacts\/html\/amyl.html. Accessed 1 December 2018."},{"issue":"2","key":"2019111600301372500_B3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2019111600301372500_B4","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2015.76","article-title":"Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia [letter]","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111600301372500_B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111600301372500_B6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111600301372500_B7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019111600301372500_B8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.leukres.2012.04.020","article-title":"Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial","volume":"36","author":"Thomas","year":"2012","journal-title":"Leuk Res"},{"issue":"9","key":"2019111600301372500_B9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajh.23498","article-title":"Outcome of older patients with acute myeloid leukemia in first relapse","volume":"88","author":"Sarkozy","year":"2013","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111600301372500_B10","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111600301372500_B11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111600301372500_B12","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/blood.V86.11.4091.bloodjournal86114091","article-title":"Plasma\/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia","volume":"86","author":"Lyman","year":"1995","journal-title":"Blood"},{"issue":"12","key":"2019111600301372500_B13","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood.V88.12.4493.bloodjournal88124493","article-title":"Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia","volume":"88","author":"Wodnar-Filipowicz","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2019111600301372500_B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2613.2008.00580.x","article-title":"Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse","volume":"89","author":"Molyneux","year":"2008","journal-title":"Int J Exp Pathol"},{"issue":"6","key":"2019111600301372500_B15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/09553000110043711","article-title":"Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia","volume":"77","author":"Bertho","year":"2001","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"2019111600301372500_B16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1084\/jem.20101459","article-title":"The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency","volume":"208","author":"Bigley","year":"2011","journal-title":"J Exp Med"},{"issue":"6","key":"2019111600301372500_B17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-07-517151","article-title":"The evolution of cellular deficiency in GATA2 mutation","volume":"123","author":"Dickinson","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111600301372500_B18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.leu.2401378","article-title":"Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes","volume":"13","author":"Zwierzina","year":"1999","journal-title":"Leukemia"},{"issue":"9","key":"2019111600301372500_B19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00277-002-0535-7","article-title":"Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy","volume":"81","author":"Bojko","year":"2002","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111600301372500_B20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/15258160260090997","article-title":"Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization","volume":"11","author":"Haidar","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"issue":"12","key":"2019111600301372500_B21","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J Clin Invest"},{"issue":"25","key":"2019111600301372500_B22","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111600301372500_B23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111600301372500_B24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111600301372500_B25","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111600301372500_B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v061.i08","article-title":"OptimalCutpoints: An R package for selecting optimal cutpoints in diagnostic tests","volume":"61","author":"Lopez-Raton","year":"2014","journal-title":"J Stat Softw"},{"issue":"8","key":"2019111600301372500_B27","first-page":"1368","article-title":"Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines","volume":"9","author":"Meierhoff","year":"1995","journal-title":"Leukemia"},{"issue":"4","key":"2019111600301372500_B28","first-page":"588","article-title":"Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"2019111600301372500_B29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","article-title":"FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111600301372500_B30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/eji.201243163","article-title":"Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses","volume":"43","author":"Saito","year":"2013","journal-title":"Eur J Immunol"},{"issue":"9","key":"2019111600301372500_B31","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood.V88.9.3371.bloodjournal8893371","article-title":"Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand","volume":"88","author":"McClanahan","year":"1996","journal-title":"Blood"},{"issue":"8","key":"2019111600301372500_B32","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood.V93.8.2595","article-title":"Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis","volume":"93","author":"Chklovskaia","year":"1999","journal-title":"Blood"},{"issue":"2","key":"2019111600301372500_B33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.20030323","article-title":"Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo","volume":"198","author":"Karsunky","year":"2003","journal-title":"J Exp Med"},{"issue":"1","key":"2019111600301372500_B34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41590-017-0001-2","article-title":"Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells","volume":"19","author":"Karamitros","year":"2018","journal-title":"Nat Immunol"},{"issue":"12","key":"2019111600301372500_B35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.24207","article-title":"Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the \u201c3\u2009+\u20097\u201d induction regimen for acute myeloid leukemia","volume":"90","author":"Ofran","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"2019111600301372500_B36","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3052\/1502783\/advancesadv2019000197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3052\/1502783\/advancesadv2019000197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:43:43Z","timestamp":1573865023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/20\/3052\/422504\/Serum-Flt3-ligand-is-a-biomarker-of-progenitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":36,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000197","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/588319","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]}}}